November is #LungCancer Awareness month 🫁 📣 Check out this NEW interview from #ESMO2023 | #MARIPOSA-2: #amivantamab + #chemo (± #lazertinib) vs #chemo in #EGFR-mutated #NSCLC post-#osimertinib 🎥 Antonio Passaro, MD, PhD, IEO European Institute of Oncology, discusses the Phase III #MARIPOSA-2 (NCT04988295) trial, exploring the effectiveness of #amivantamab (ami) in combination with #carboplatin-pemetrexed (chemo) with or without #lazertinib (laz) in patients with #EGFR-mutated advanced #nonsmallcelllungcancer (#NSCLC) who had experienced disease progression on #osimertinib ⭐ The trial demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and intracranial PFS for both ami-chemo and ami-laz-chemo compared to chemo alone ⭐ The interim overall-survival (OS) data showed promising trends. Hematologic, #EGFR, and MET-related adverse events were observed in the ami-containing arms, with lower #hematologic #toxicity in the ami-#chemo arm ⭐ Longer-term follow-up is needed to assess the impact of regimen modifications on #safety and #efficacy These findings suggest that ami-chemo and ami-laz-chemo could become a new standard of care for #EGFR-mutated advanced #NSCLC patients who progressed on #osimertinib 🔦 Give it a watch to learn more 👉 https://lnkd.in/eMnRiFC5 #Oncology ESMO - European Society for Medical Oncology #LungCancerAwarenessMonth #LCsm
